Loading...

Buy Full Version
"Varicella Live Vaccine Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Varicella Live Vaccine Market by Product (Monovalent Varicella Vaccine and Combination Varicella Vaccine), Application (Chickenpox Immunization, Herpes Zoster Immunization, and MMRV Immunization), and Provider (Public Provider, and Private Provider): Global Opportunity Analysis and Industry Forecast, 2018–2026

A03969
Pages: 178
Oct 2019 | 1657 Views
 
Author(s) : Sanjivan Gill , Onkar Sumant
Tables: 109
Charts: 32
 

Varicella Live Vaccine Market Outlook-2026

The global varicella live vaccine market was valued at $2,714 million in 2018, and is expected to reach $4,222 million by 2026, registering a CAGR of 5.7% from 2019 to 2026.

Varicella zoster is also known as Human alphaherpesvirus 3 and causes chicken pox and herpes zoster in humans. The infection caused by this virus can be prevented by the use of vaccinations that are specially formulated to provide immunity against the virus. There are mainly two types of vaccinations available to provide immunity against varicella zoster such as monovalent varicella vaccine and combination varicella vaccine. These vaccines differ from each other on the basis of their contents. For instance, monovalent varicella vaccine contains only one strain of virus whereas the combination varicella vaccine contains more than one strain of virus and offers immunity against more than one virus.

Varicella Live Vaccine Market

Get more information on this report : Request Sample Pages

Surge in immunization programs across the globe is the major factor that boosts the growth of the varicella live vaccine market. Furthermore, increase in awareness related to the use of varicella live vaccines and rise in adoption of varicella vaccination worldwide also fuel the varicella live vaccine market growth. However, high monetary inputs associated with the production of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.

VARICELLA LIVE VACCINE MARKET SEGMENTATION

The global varicella live vaccine market size is studied based on product, application, provider, and region. On the basis of product, the market is bifurcated into monovalent varicella vaccine and combination varicella vaccine. By application, it is divided into chicken pox immunization, herpes zoster immunization and measles, mumps, rubella, and varicella (MMRV) immunization. On the basis of provider, it is segmented into public provider and private provider. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and, rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Segment Review

Based on product, the monovalent varicella vaccine segment occupied the largest varicella live vaccine market share in 2018. Moreover, monovalent varicella vaccine segment is also expected to experience rapid growth during the forecast period as these vaccines exhibit lesser chances of inducing febrile seizures in children as compared to combination vaccines. Moreover, easy availability and presence of large number of products are the other factors that boost the varicella vaccine market growth.

Varicella Live Vaccine Market
By Product

Your browser does not support the canvas element.

Monovalent Varicella Vaccine segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Based on application, the varicella live vaccine market is classified into chicken pox immunization, herpes zoster immunization and measles, mumps, rubella, and varicella (MMRV) immunization. Chicken pox immunization acquired the largest varicella live vaccine market share owing to vaccination employed with an initial aim of building immunity against chicken pox. The herpes zoster segment is expected to experience rapid growth during the forecast period owing to surge in geriatric population worldwide and rise in awareness about the use of varicella live vaccines for herpes zoster.

Varicella Live Vaccine Market
By Application

Your browser does not support the canvas element.

Herpes zoster is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

By region, North America accounted for the major share of the varicella live vaccine market in 2018 and is expected to continue this trend owing to easy availability of varicella live vaccines, presence of skilled healthcare experts, and presence of major key players that offer varicella live vaccines. Asia-Pacific is expected to grow at the fastest rate during the forecast period due to surge in awareness related to importance of immunization and rise in disposable income. The developing economies offer lucrative opportunities for varicella live vaccine providers to expand their business. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, Malaysia, and others.

Varicella Live Vaccine Market
By Region

2026
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 7.0% during 2019-2026.

Get more information on this report : Request Sample Pages

The global varicella live vaccine market is highly competitive and the prominent players in the market have adopted various strategies for garnering maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Bio-Med Pvt. Limited, Changchun BCHT Biotechnology Co. Ltd., Emcure Pharmaceuticals Limited, GlaxoSmithKline plc, Green Cross Holdings (GC Pharma), Merck & Co. Inc., Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation), Novo Medi Sciences Pvt. Ltd., Sanofi, and Takeda Pharmaceutical Company Limited.

Key Benefits for Varicella Live Vaccine Market:

  • This report entails a detailed quantitative analysis along with the current global varicella live vaccine market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The varicella live vaccine market forecast is studied from 2019 to 2026. 
  • The market size and estimations are based on a comprehensive analysis of key developments in the varicella live vaccine industry. 
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Varicella Live Vaccine Key Market Segments:

By Product

  • Monovalent Varicella Vaccine 
  • Combination Varicella Vaccine

By Application

  • Chickenpox Immunization
  • Herpes Zoster Immunization
  • Measles, Mumps, Rubella and Varicella (MMRV) Immunization

By Provider

  • Public Provider 
  • Private Provider

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany 
    • France 
    • UK 
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan 
    • China 
    • India 
    • Australia 
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil 
    • Saudi Arabia 
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Porter's five forces analysis

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Thereat of new entrants
3.3.4. Threat of substitutes
3.3.5. Intensity of competitive rivalry

3.4. Top player positioning, 2018
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Surge in immunization programs across the globe
3.5.1.2. Rise in awareness regarding use of varicella live vaccines
3.5.1.3. Increase in adoption of varicella live vaccines

3.5.2. Restraint

3.5.2.1. High monetary inputs associated with the production

3.5.3. Opportunity

3.5.3.1. High growth potential in emerging economies

3.5.4. Impact analysis

CHAPTER 4: VARICELLA LIVE VACCINE MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Monovalent varicella vaccine

4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Combination varicella vaccine

4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

CHAPTER 5: VARICELLA LIVE VACCINE MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Chickenpox Immunization

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Herpes zoster immunization

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Mumps, measles, rubella & varicella (MMRV) Immunization

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: VARICELLA VACCINE MARKET, BY PROVIDER

6.1. Overview

6.1.1. Market size and forecast

6.2. Public

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Private

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

CHAPTER 7: VARICELLA LIVE VACCINE MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends and opportunities
7.2.2. Market analysis by country

7.2.2.1. U.S.

7.2.2.1.1. U.S. market size and forecast, by product
7.2.2.1.2. U.S. market size and forecast, by application
7.2.2.1.3. U.S. market size and forecast, by provider

7.2.2.2. Canada

7.2.2.2.1. Canada market size and forecast, by product
7.2.2.2.2. Canada market size and forecast, by application
7.2.2.2.3. Canada market size and forecast, by provider

7.2.2.3. Mexico

7.2.2.3.1. Mexico market size and forecast, by product
7.2.2.3.2. Mexico market size and forecast, by application
7.2.2.3.3. Mexico market size and forecast, by provider

7.2.3. North America market size and forecast, by product
7.2.4. North America market size and forecast, by application
7.2.5. North America market size and forecast, by provider

7.3. Europe

7.3.1. Key market trends and opportunities
7.3.2. Market analysis by country

7.3.2.1. Germany

7.3.2.1.1. Germany market size and forecast, by product
7.3.2.1.2. Germany market size and forecast, by application
7.3.2.1.3. Germany market size and forecast, by provider

7.3.2.2. France

7.3.2.2.1. France market size and forecast, by product
7.3.2.2.2. France market size and forecast, by application
7.3.2.2.3. France market size and forecast, by provider

7.3.2.3. UK

7.3.2.3.1. UK market size and forecast, by product
7.3.2.3.2. UK market size and forecast, by application
7.3.2.3.3. UK market size and forecast, by provider

7.3.2.4. Italy

7.3.2.4.1. Italy market size and forecast, by product
7.3.2.4.2. Italy market size and forecast, by application
7.3.2.4.3. Italy market size and forecast, by provider

7.3.2.5. Spain

7.3.2.5.1. Spain market size and forecast, by product
7.3.2.5.2. Spain market size and forecast, by application
7.3.2.5.3. Spain market size and forecast, by provider

7.3.2.6. Rest of Europe

7.3.2.6.1. Rest of Europe market size and forecast, by product
7.3.2.6.2. Rest of Europe market size and forecast, by application
7.3.2.6.3. Rest of Europe market size and forecast, by provider

7.3.3. Europe market size and forecast, by product
7.3.4. Europe market size and forecast, by application
7.3.5. Europe market size and forecast, by provider

7.4. Asia-Pacific

7.4.1. Key market trends and opportunities
7.4.2. Market analysis by country

7.4.2.1. Japan

7.4.2.1.1. Japan market size and forecast, by product
7.4.2.1.2. Japan market size and forecast, by application
7.4.2.1.3. Japan market size and forecast, by provider

7.4.2.2. China

7.4.2.2.1. China market size and forecast, by product
7.4.2.2.2. China market size and forecast, by application
7.4.2.2.3. China market size and forecast, by provider

7.4.2.3. Australia

7.4.2.3.1. Australia market size and forecast, by product
7.4.2.3.2. Australia market size and forecast, by application
7.4.2.3.3. Australia market size and forecast, by provider

7.4.2.4. India

7.4.2.4.1. India market size and forecast, by product
7.4.2.4.2. India market size and forecast, by application
7.4.2.4.3. India market size and forecast, by provider

7.4.2.5. South Korea

7.4.2.5.1. South Korea market size and forecast, by product
7.4.2.5.2. South Korea market size and forecast, by application
7.4.2.5.3. South Korea market size and forecast, by provider

7.4.2.6. Rest of Asia-Pacific

7.4.2.6.1. Rest of Asia-Pacific market size and forecast, by product
7.4.2.6.2. Rest of Asia-Pacific market size and forecast, by application
7.4.2.6.3. Rest of Asia-Pacific market size and forecast, by provider

7.4.3. Asia-Pacific market size and forecast, by product
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by provider

7.5. LAMEA

7.5.1. Key market trends and opportunities
7.5.2. Market analysis by country

7.5.2.1. Brazil

7.5.2.1.1. Brazil market size and forecast, by product
7.5.2.1.2. Brazil market size and forecast, by application
7.5.2.1.3. Brazil market size and forecast, by provider

7.5.2.2. Saudi Arabia

7.5.2.2.1. Saudi Arabia market size and forecast, by product
7.5.2.2.2. Saudi Arabia market size and forecast, by application
7.5.2.2.3. Saudi Arabia market size and forecast, by provider

7.5.2.3. South Africa

7.5.2.3.1. South Africa market size and forecast, by product
7.5.2.3.2. South Africa market size and forecast, by application
7.5.2.3.3. South Africa market size and forecast, by provider

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Rest of LAMEA market size and forecast, by product
7.5.2.4.2. Rest of LAMEA market size and forecast, by application
7.5.2.4.3. Rest of LAMEA market size and forecast, by provider

7.5.3. LAMEA market size and forecast, by product
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by provider

CHAPTER 8: COMPANY PROFILES

8.1. BIO-MED PVT. LIMITED

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Product portfolio
8.1.4. Key strategic moves and developments

8.2. CHANGCHUN BCHT BIOTECHNOLOGY CO. LTD.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Product portfolio

8.3. EMCURE PHARMACEUTICALS LIMITED (ZUVENTUS HEALTHCARE LTD.)

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Product portfolio

8.4. GLAXOSMITHKLINE PLC

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance

8.5. GREEN CROSS HOLDINGS (GC PHARMA)

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Product portfolio
8.5.4. Business performance

8.6. MERCK & CO. INC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. MITSUBISHI CHEMICAL HOLDINGS CORPORATION (MITSUBISHI TANABE PHARMA CORPORATION)

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. NOVO MEDI SCIENCES PVT. LTD.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Product portfolio

8.9. SANOFI

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance

8.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL VARICELLA LIVE VACCINE MARKET, BY PRODUCTS, 2018–2026 ($MILLION)
TABLE 02. VARICELLA LIVE VACCINE MARKET FOR MONOVALENT VARICELLA VACCINE, BY REGION, 2018–2026 ($MILLION)
TABLE 03. VARICELLA LIVE VACCINE MARKET FOR COMBINATION VARICELLA VACCINE, BY REGION, 2018–2026 ($MILLION)
TABLE 04. GLOBAL VARICELLA LIVE VACCINE MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 05. VARICELLA LIVE VACCINE MARKET FOR CHICKENPOX IMMUNIZATION, BY REGION, 2018–2026 ($MILLION)
TABLE 06. VARICELLA LIVE VACCINE MARKET FOR HERPES ZOSTER, BY REGION, 2018–2026 ($MILLION)
TABLE 07. VARICELLA LIVE VACCINE MARKET FOR MMRV IMMUNIZATION, BY REGION, 2018–2026 ($MILLION)
TABLE 08. GLOBAL VARICELLA LIVE VACCINE MARKET, BY PROVIDER, 2018–2026 ($MILLION)
TABLE 09. VARICELLA LIVE VACCINE MARKET FOR PUBLIC  PROVIDER, BY REGION, 2018–2026 ($MILLION)
TABLE 10. VARICELLA LIVE VACCINE MARKET FOR PRIVATE PROVIDER, BY REGION, 2018–2026 ($MILLION)
TABLE 11. VARICELLA LIVE VACCINE MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 12. NORTH AMERICA VARICELLA LIVE VACCINE MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)
TABLE 13. U.S. VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 14. U.S. VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 15. U.S. VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 16. CANADA VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 17. CANADA VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 18. CANADA VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 19. MEXICO VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 20. MEXICO VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 21. MEXICO VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 22. NORTH AMERICA VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026($MILLION)
TABLE 23. NORTH AMERICA VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026($MILLION)
TABLE 24. NORTH AMERICA VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026($MILLION)
TABLE 25. EUROPE VARICELLA LIVE VACCINE MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)
TABLE 26. GERMANY VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 27. GERMANY VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 28. GERMANY VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 29. FRANCE VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 30. FRANCE VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 31. FRANCE VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 32. UK VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 33. UK VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 34. UK VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 35. ITALY VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 36. ITALY VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 37. ITALY VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 38. SPAIN VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 39. SPAIN VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 40. SPAIN VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 41. REST OF EUROPE VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 42. REST OF EUROPE VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 43. REST OF EUROPE VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 44. EUROPE VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026($MILLION)
TABLE 45. EUROPE VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026($MILLION)
TABLE 46. EUROPE VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026($MILLION)
TABLE 47. ASIA-PACIFIC VARICELLA LIVE VACCINE MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)
TABLE 48. JAPAN VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 49. JAPAN VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 50. JAPAN VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 51. CHINA VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 52. CHINA VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 53. CHINA VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 54. AUSTRALIA VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 55. AUSTRALIA VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 56. AUSTRALIA VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 57. INDIA VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 58. INDIA VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 59. INDIA VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 60. SOUTH KOREA VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 61. SOUTH KOREA VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 62. SOUTH KOREA VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 63. REST OF ASIA-PACIFIC VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 64. REST OF ASIA-PACIFIC VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 65. REST OF ASIA-PACIFIC VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 66. ASIA-PACIFIC VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026($MILLION)
TABLE 67. ASIA-PACIFIC VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026($MILLION)
TABLE 68. ASIA-PACIFIC VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026($MILLION)
TABLE 69. LAMEA VARICELLA LIVE VACCINE MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)
TABLE 70. BRAZIL VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 71. BRAZIL VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 72. BRAZIL VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 73. SAUDI ARABIA VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 74. SAUDI ARABIA VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 75. SAUDI ARABIA VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 76. SOUTH AFRICA VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 77. SOUTH AFRICA VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 78. SOUTH AFRICA VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 79. REST OF LAMEA VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026 ($MILLION)
TABLE 80. REST OF LAMEA VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026 ($MILLION)
TABLE 81. REST OF LAMEA VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026 ($MILLION)
TABLE 82. LAMEA VARICELLA LIVE VACCINE MARKET REVENUE, BY PRODUCT 2019–2026($MILLION)
TABLE 83. LAMEA VARICELLA LIVE VACCINE MARKET REVENUE, BY APPLICATION 2019–2026($MILLION)
TABLE 84. LAMEA VARICELLA LIVE VACCINE MARKET REVENUE, BY PROVIDER 2019–2026($MILLION)
TABLE 85. BIO-MED: COMPANY SNAPSHOT
TABLE 86. BIO-MED: PRODUCT PORTFOLIO
TABLE 87. CHANGCHUN BAIKE: COMPANY SNAPSHOT
TABLE 88. CHANGCHUN BAIKE: PRODUCT PORTFOLIO
TABLE 89. EMCURE : COMPANY SNAPSHOT
TABLE 90. EMCURE: PRODUCT PORTFOLIO
TABLE 91. GSK: COMPANY SNAPSHOT
TABLE 92. GSK: OPERATING SEGMENTS
TABLE 93. GSK: PRODUCT PORTFOLIO
TABLE 94. GC: COMPANY SNAPSHOT
TABLE 95. GC: PRODUCT PORTFOLIO
TABLE 96. MERCK: COMPANY SNAPSHOT
TABLE 97. MERCK: OPERATING SEGMENTS
TABLE 98. MERCK: PRODUCT PORTFOLIO
TABLE 99. MCHC GROUP: COMPANY SNAPSHOT
TABLE 100. MCHC GROUP: OPERATING SEGMENTS
TABLE 101. MCHC GROUP: PRODUCT PORTFOLIO
TABLE 102. NOVO: COMPANY SNAPSHOT
TABLE 103. NOVO: PRODUCT PORTFOLIO
TABLE 104. SANOFI: COMPANY SNAPSHOT
TABLE 105. SANOFI: OPERATING SEGMENTS
TABLE 106. SANOFI: PRODUCT PORTFOLIO
TABLE 107. TAKEDA: COMPANY SNAPSHOT
TABLE 108. TAKEDA: OPERATING SEGMENTS
TABLE 109. TAKEDA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. GLOBAL VARICELLA LIVE VACCINE MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS, 2018
FIGURE 03. MODERATE BARGAINING POWER OF BUYERS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE COMPETITIVE RIVALRY
FIGURE 08. TOP PLAYER POSITIONING, 2018
FIGURE 09. IMPACT ANALYSIS, VARICELLA LIVE VACCINE MARKET
FIGURE 10. COMPARATIVE ANALYSIS OF VARICELLA LIVE VACCINE MARKET FOR MONOVAENT VACCINE, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF VARICELLA LIVE VACCINE MARKET FOR COMBINATION VARICELLA VACCINE, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF VARICELLA LIVE VACCINE MARKET FOR CHICKENPOX IMMUNIZATION, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF VARICELLA LIVE VACCINE MARKET FOR HERPES ZOSTER, BY COUNTRY,  2018 & 2026 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF VARICELLA LIVE VACCINE MARKET FOR MMRV IMMUNIZATION, BY COUNTRY,  2018 & 2026 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF VARICELLA LIVE VACCINE MARKET FOR PUBLIC PROVIDER, BY COUNTRY,  2018 & 2026 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF VARICELLA LIVE VACCINE MARKET FOR PRIVATE PROVIDER, BY COUNTRY,  2018 & 2026 ($MILLION)
FIGURE 17. GSK: NET SALES, 2016–2018 ($MILLION)
FIGURE 18. GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 19. GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 20. GC: NET SALES, 2015–2017 ($MILLION)
FIGURE 21. GC: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 22. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 24. MERCK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 25. MCHC GROUP: NET SALES, 2016–2018 ($MILLION)
FIGURE 26. MCHC GROUP: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 27. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 28. SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 29. SANOFI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 30. TAKEDA: NET SALES, 2016–2018 ($MILLION)
FIGURE 31. TAKEDA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 32. TAKEDA: REVENUE SHARE BY REGION, 2018 (%)

 
 

Varicella live vaccines are expected to witness high adoption in the near future, owing to increase in number of immunization programs across the globe. In addition, the market is exhibiting high growth rate, owing to surge in awareness about use of the varicella live vaccine market. Moreover, rise in adoption of varicella live vaccines is another factor that fuels the growth of the market. Asia-Pacific and LAMEA are expected to offer lucrative growth opportunities to the key players. This is majorly attributed to factors such as improvement in healthcare facilities, rise in disposable income, and rapid improvement in economic conditions. However, high monetary inputs required for the production of these vaccines hinders the growth of the varicella live vaccine market. Varicella live vaccine manufacturers and distributors have focused on expanding their presence in the emerging economies to strengthen their foothold in the market.

North America garnered the largest share of this market due to rise in immunization programs, easy availability of varicella live vaccine products, and presence of skilled healthcare professionals.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Varicella Live Vaccine Market

  • Online Only
  • $3,456  $3,041
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,379
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370  $4,296
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $4,838
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995  $6,297
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample